Acid alpha-glucosidase deficiency (Pompe disease)
- PMID: 17217857
- DOI: 10.1007/s11910-007-0024-4
Acid alpha-glucosidase deficiency (Pompe disease)
Abstract
The development and recent approval of recombinant acid alpha-glucosidase for enzyme replacement therapy have been major milestones in Pompe disease research. Acid alpha-glucosidase is the enzyme responsible for degradation of glycogen polymers to glucose in the acidic milieu of the lysosomes. Cardiac and skeletal muscles are the two major tissues affected by the accumulation of glycogen within the lysosomes. Both cardiomyopathy and skeletal muscle myopathy are observed in patients with complete enzyme deficiency; this form of the disease is fatal within the first year of life. Skeletal muscle myopathy eventually leading to respiratory insufficiency is the predominant manifestation of partial enzyme deficiency. The recombinant enzyme alglucosidase alfa is the first drug ever approved for this devastating disorder. This review discusses the benefits and the shortcomings of the new therapy.
Similar articles
-
Autophagy and lysosomes in Pompe disease.Autophagy. 2006 Oct-Dec;2(4):318-20. doi: 10.4161/auto.2984. Epub 2006 Oct 5. Autophagy. 2006. PMID: 16874053
-
Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.Mol Ther. 2005 Jan;11(1):48-56. doi: 10.1016/j.ymthe.2004.09.017. Mol Ther. 2005. PMID: 15585405
-
Desensitization of two young patients with infantile-onset Pompe disease and severe reactions to alglucosidase alfa.Neurol Sci. 2019 Jul;40(7):1453-1455. doi: 10.1007/s10072-019-03744-3. Epub 2019 Feb 18. Neurol Sci. 2019. PMID: 30778879
-
Pompe Disease: New Developments in an Old Lysosomal Storage Disorder.Biomolecules. 2020 Sep 18;10(9):1339. doi: 10.3390/biom10091339. Biomolecules. 2020. PMID: 32962155 Free PMC article. Review.
-
Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.Acta Neurol Belg. 2006 Jun;106(2):82-6. Acta Neurol Belg. 2006. PMID: 16898258 Review.
Cited by
-
Engineered skeletal muscles for disease modeling and drug discovery.Biomaterials. 2019 Nov;221:119416. doi: 10.1016/j.biomaterials.2019.119416. Epub 2019 Aug 8. Biomaterials. 2019. PMID: 31419653 Free PMC article. Review.
-
Late-onset Pompe disease with complicated intracranial aneurysm: a Chinese case report.Neuropsychiatr Dis Treat. 2016 Mar 29;12:713-7. doi: 10.2147/NDT.S94892. eCollection 2016. Neuropsychiatr Dis Treat. 2016. PMID: 27099502 Free PMC article.
-
Autophagy in the cellular energetic balance.Cell Metab. 2011 May 4;13(5):495-504. doi: 10.1016/j.cmet.2011.04.004. Cell Metab. 2011. PMID: 21531332 Free PMC article. Review.
-
PDGF-BB serum levels are decreased in adult onset Pompe patients.Sci Rep. 2019 Feb 14;9(1):2139. doi: 10.1038/s41598-018-38025-0. Sci Rep. 2019. PMID: 30765719 Free PMC article.
-
When more is less: excess and deficiency of autophagy coexist in skeletal muscle in Pompe disease.Autophagy. 2009 Jan;5(1):111-3. doi: 10.4161/auto.5.1.7293. Epub 2009 Jan 30. Autophagy. 2009. PMID: 19001870 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous